Claimant scorecard · AERS v2.1 · Calibrating
FDA
1 claim tracked in the Responsibility Ledger. 1 pending grade.
AERS
—
Insufficient closed grades
Pending
1
Open horizons
Closed
0
Graded outcomes
First tracked
Apr 29, 2026
Open horizons
FDA: AI integrated across all centers by June 30, 2025 (now delayed to 2026)
Invalidator — Fewer than 90% of FDA centers operationally deployed AI systems by July 2025, or credible third-party reporting (via GAO, Inspector General audits, or investigative journalism) demonstrates that AI systems were pulled back, materially restricted, or introduced systematic errors that delayed drug reviews rather than accelerated them.
About this scorecard
The AI Execution Risk Score (AERS) is a 0-100 metric quantifying the gap between FDA’s public AI claims and demonstrated delivery. Higher AERS = stronger track record. Each claim above is drawn from a primary source linked in the original Ledger entry; the horizon date is when the claim becomes graded under the published methodology. Materiality is the editor’s assessment of the claim’s formality from 1 (PR statement) to 5 (earnings call or SEC filing).
AERS v2.1 · Methodology in active calibration · Not investment advice.